Back to Projects

Imaging nuclear factor erythroid 2-related factor 2: the master regulator of the tumour antioxidant response

Project ID: 2018_D16

Student: Eman Khalil

1st supervisor: Tim Witney, King’s College London
2nd supervisor: Gilbert Fruhwirth, King’s College London

Nrf2 is a redox-sensitive transcription factor that acts as the master regulator of the cellular antioxidant response (Milkovic, Zarkovic et al. 2017). Through the binding to the antioxidant response element (ARE) of key gene promotors, Nrf2 regulates a transcriptional programme that encompasses multiple antioxidant genes, xenobiotic detoxification enzymes and drug efflux pumps. (Jaramillo and Zhang 2013)

Figure 1. The description is in the caption below.

Fig. 1.  KEAP1 controls Nrf2 expression through targeting for proteosomal degradation. Under oxidative stress, conformational changes in KEAP1 results in Nrf2 accumulation, translocation to the nucleus and transcriptional activation of numerous antioxidant genes.

Nrf2 plays a critical role in both tumour initiation and progression. Whilst Nrf2-regulated gene expression confers cytoprotection in healthy tissue, acting to prevent against carcinogenesis, constitutive activation of Nrf2 has been established as a primary resistance factor in cancer.(Jaramillo and Zhang 2013) Kelch-like ECH-associated protein 1 (KEAP1) negatively regulates Nrf2 activity through direct binding and tagging of Nrf2 for proteasomal degradation (Fig. 1). Somatic loss-of-function mutations in KEAP1 are frequently found in drug-resistant non-small cell lung cancer (NSCLC) tumours – a disease with a ten-year survival rate of just 5% (Wang, Sun et al. 2008, Solis, Behrens et al. 2010).

This research will seek to develop the first imaging agent to enable the temporal and spatial assessment of Nrf2 expression in living subjects. We will develop novel Nrf2 radiotracers based on the structures of existing high-affinity Nrf2-binders, ML385 (Singh, Venkannagari et al. 2016) and AEM1 (Bollong, Yun et al. 2015) (Fig. 2). Both ML385 and AEM1 represent best-in-class Nrf2 inhibitors, with half maximal inhibitory activities of Nrf2-DNA binding at submicromolar potencies, resulting in a down-regulation of Nrf2-target genes, sensitisation to chemotherapies, and a reduction in NSCLC tumour growth in vivo. (Bollong, Yun et al. 2015, Singh, Venkannagari et al. 2016)

Figure 2. The description is in the caption below.

Fig. 2.  Structures of putative Nrf2 radiotracers. Structures are based on known Nrf2 inhibitors, ML385 (i) and AEM1 (ii) labelled with the positron emitter, fluorine-18.

Given the excellent pharmacodynamic profile of ML385 and AEM1, we will use these chemical structures to develop novel Nrf2 radiotracers, through their radiolabelling with fluorine-18. Precursors for labelling will be synthesised with labile leaving groups to allow rapid and reproducible radiofluorination according to previously published methodology (Tredwell, Preshlock et al. 2014) (Fig. 3). We will assess radiotracer uptake and binding specificity in A549 NSCLC cells in culture which harbour a mutation in KEAP1. Time course of radiotracer uptake and retention will be performed in Nrf2 wild-type (WT), Nrf2 knockout and Nrf2 overexpressing cells. A lead candidate radiotracer (18F-NRF2) will be selected based on magnitude of cell uptake and specificity for Nrf2.  In addition, we will assess 18F-NRF2 pharmokinetics and in vivo stability following intravenous injection of the radiotracer.

Figure 3. The description is in the caption below.

Fig. 3. Suggested radiolabelling strategies for AEM1 (i) and ML385 (ii) compound classes

Chemotherapeutic agents have been shown to induce oxidative stress in cancer patients (Clemens, Ladner et al. 1990, Durken, Agbenu et al. 1995, Erhola, Kellokumpu-Lehtinen et al. 1996). Given that Nrf2 is induced following therapy to counteract oxidative stress (Mullany and Richards 2012)), a non-invasive measure of tumour Nrf2 will provide an early assessment of drug efficacy. Using Nrf2 WT and Nrf2-/- isogenic cells and tumour-bearing mice, we will assess the ability of 18F-NRF2 to monitor cisplatin-induced changes in Nrf2. It is hoped that through 18F-NRF2 imaging the oncologist will be able to identify NSCLC patients that are refractory to standard-of-care, allowing the transferral of drug-resistant patients to alternative therapies, thereby improving outcomes in this devastating disease.

Back to Projects